Compare Stocks: LITS, NAKA, DFDV, and HSDT

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DFDV DeFi Development	$5.25 -2.2%	$4.42	$2.44 ▼ $18.28	$162.74M	-3.59	2.44 million shs	2.33 million shs
HSDT Solana	$2.63 +0.4%	$2.17	$1.18 ▼ $20.50	$159.73M	1.11	544,611 shs	481,044 shs
LITS Lite Strategy	$1.38 +0.4%	$1.07	$0.69 ▼ $2.97	$41.96M	0.17	930,461 shs	1.01 million shs
NAKA KindlyMD	$9.66 +6.0%	$7.12	$3.33 ▼ $46.40	$172.87M	15.82	224,632 shs	362,065 shs

10 Best Stocks to Own in Fall 2026

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DFDV DeFi Development	0.00%	-13.08%	-13.65%	+59.09%	-65.53%
HSDT Solana	0.00%	-10.54%	+11.91%	+46.93%	-82.42%
LITS Lite Strategy	0.00%	-4.17%	+32.69%	+45.20%	-46.09%
NAKA KindlyMD	0.00%	-3.30%	+16.25%	+150.26%	-78.63%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DFDV DeFi Development	$5.25 -2.2%	$4.42	$2.44 ▼ $18.28	$162.74M	-3.59	2.44 million shs	2.33 million shs
HSDT Solana	$2.63 +0.4%	$2.17	$1.18 ▼ $20.50	$159.73M	1.11	544,611 shs	481,044 shs
LITS Lite Strategy	$1.38 +0.4%	$1.07	$0.69 ▼ $2.97	$41.96M	0.17	930,461 shs	1.01 million shs
NAKA KindlyMD	$9.66 +6.0%	$7.12	$3.33 ▼ $46.40	$172.87M	15.82	224,632 shs	362,065 shs

10 Best Stocks to Own in Fall 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DFDV DeFi Development	0.00%	-13.08%	-13.65%	+59.09%	-65.53%
HSDT Solana	0.00%	-10.54%	+11.91%	+46.93%	-82.42%
LITS Lite Strategy	0.00%	-4.17%	+32.69%	+45.20%	-46.09%
NAKA KindlyMD	0.00%	-3.30%	+16.25%	+150.26%	-78.63%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DFDV DeFi Development	2.00	Hold	$10.40	98.10% Upside
HSDT Solana	2.25	Hold	$4.00	52.09% Upside
LITS Lite Strategy	1.00	Sell	N/A	N/A
NAKA KindlyMD	2.40	Hold	$20.00	107.04% Upside

Current Analyst Ratings Breakdown

Latest LITS, NAKA, DFDV, and HSDT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/24/2026	LITS Lite Strategy	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
9/22/2026	DFDV DeFi Development	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold (C) ➝ Sell (D-)
9/22/2026	HSDT Solana	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$3.50 ➝ $4.00
9/22/2026	NAKA KindlyMD	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$11.00 ➝ $13.00
9/10/2026	DFDV DeFi Development	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$4.70 ➝ $10.40
9/8/2026	LITS Lite Strategy	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
9/3/2026	HSDT Solana	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
9/3/2026	HSDT Solana	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$2.50 ➝ $3.50
9/3/2026	NAKA KindlyMD	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$9.00 ➝ $11.00
8/21/2026	LITS Lite Strategy	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/17/2026	HSDT Solana	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$3.00 ➝ $2.50

(Data available from 10/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DFDV DeFi Development	$11.39M	14.29	$0.89 per share	5.90	$3.12 per share	1.68
HSDT Solana	$6.02M	26.54	N/A	N/A	$6.88 per share	0.38
LITS Lite Strategy	$65.30M	0.64	N/A	N/A	$1.22 per share	1.13
NAKA KindlyMD	$1.82M	95.01	N/A	N/A	$46.97 per share	0.21

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DFDV DeFi Development	-$73.79M	-$9.98	N/A	N/A	N/A	-1,319.45%	17.97%	5.02%	N/A
HSDT Solana	-$40.89M	-$30.32	N/A	20.23	N/A	-1,302.78%	-41.86%	-18.53%	11/17/2026 (Estimated)
LITS Lite Strategy	-$71.15M	-$1.98	N/A	N/A	N/A	N/A	-97.27%	-95.90%	N/A
NAKA KindlyMD	-$52.23M	-$35.85	N/A	N/A	N/A	-1,067.93%	-63.45%	-41.04%	N/A

Latest LITS, NAKA, DFDV, and HSDT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/28/2026	Q4 2026	LITS Lite Strategy	N/A	-$0.38	N/A	-$0.38	N/A	N/A
8/14/2026	Q2 2026	HSDT Solana	-$0.02	-$0.38	-$0.36	-$0.38	$3.50 million	$2.53 million
8/13/2026	Q2 2026	NAKA KindlyMD	N/A	-$6.65	N/A	-$6.65	N/A	$35.87 million
8/12/2026	Q2 2026	DFDV DeFi Development	N/A	-$0.21	N/A	-$1.00	N/A	$3.31 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
DFDV DeFi Development	N/A	N/A	N/A	N/A	N/A
HSDT Solana	N/A	N/A	N/A	N/A	N/A
LITS Lite Strategy	N/A	N/A	N/A	N/A	N/A
NAKA KindlyMD	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DFDV DeFi Development	12.53	1.27	1.27
HSDT Solana	N/A	13.31	13.31
LITS Lite Strategy	N/A	5.74	5.74
NAKA KindlyMD	N/A	0.15	0.15

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DFDV DeFi Development	0.48%
HSDT Solana	18.63%
LITS Lite Strategy	52.38%
NAKA KindlyMD	N/A

Insider Ownership

Company	Insider Ownership
DFDV DeFi Development	23.61%
HSDT Solana	14.40%
LITS Lite Strategy	1.60%
NAKA KindlyMD	24.49%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DFDV DeFi Development	16	31.00 million	23.68 million	N/A
HSDT Solana	21	60.74 million	51.99 million	Not Optionable
LITS Lite Strategy	100	30.41 million	29.92 million	N/A
NAKA KindlyMD	N/A	17.90 million	13.51 million	N/A

LITS, NAKA, DFDV, and HSDT Headlines

Recent News About These Companies

KindlyMD, Inc. (NASDAQ:NAKA) Stock Has Consensus Price Target of $20.00

October 2 at 4:15 AM | americanbankingnews.com

KindlyMD, Inc. (NASDAQ:NAKA) Stock Has Average Price Target of $20.00 According to Analysts

October 2 at 4:13 AM | marketbeat.com

B. Riley Financial Boosts KindlyMD (NASDAQ:NAKA) Price Target to $13.00

September 22, 2026 | marketbeat.com

KindlyMD, Inc. (NASDAQ:NAKA) Given Consensus Rating of "Hold" by Brokerages

September 7, 2026 | marketbeat.com

Nakamoto shares plunge 99% from peak as company pivots to acquisitions

September 2, 2026 | cryptobriefing.comC

KindlyMD (NASDAQ:NAKA) CEO David Bailey Buys 32,134 Shares of Stock

August 22, 2026 | insidertrades.com

KindlyMD (NASDAQ:NAKA) CEO Purchases $25,180.16 in Stock

August 21, 2026 | insidertrades.com

Nakamoto Reports Second Quarter 2026 Financial and Operating Results

August 13, 2026 | businesswire.com

Nakamoto Launches Intelligence 2027, a New Flagship Event for the AI Economy

August 12, 2026 | businesswire.com

KindlyMD, Inc. (NASDAQ:NAKA) Receives $30.00 Consensus Target Price from Brokerages

July 22, 2026 | defenseworld.netD

Nasdaq-listed firm makes a drastic move to go all in on Bitcoin

June 24, 2026 | thestreet.com

Clear Street Executes First Bitcoin Depositary Receipt Trade Through Prime Brokerage Platform

June 23, 2026 | globenewswire.com

Nakamoto Announces Closing of Legacy Healthcare Clinics

June 22, 2026 | businesswire.com

KindlyMD (NASDAQ:NAKA) CEO David Bailey Acquires 31,500 Shares

May 29, 2026 | insidertrades.com

Nakamoto Chairman and CEO David Bailey Purchases Additional Shares of Common Stock

May 28, 2026 | businesswire.com

Nakamoto Announces Expansion of Board of Directors

May 22, 2026 | businesswire.com

Battered stock attempts reverse split to avoid Nasdaq delisting

May 20, 2026 | thestreet.com

Following Stockholder Approval, Nakamoto Announces 1-for-40 Reverse Stock Split to be Effective on May 22, 2026

May 20, 2026 | businesswire.com

Bitcoin Magazine Announces BM TV: A Daily Markets Broadcast Network for Bitcoin's Institutional Era

April 27, 2026 | businesswire.com

UTXO Management Announces UTXO Preferred Income Strategies LP, a Dual-Class Structured Income Fund Targeting Digital Credit Preferred Securities

April 27, 2026 | businesswire.com

Nakamoto Announces Actively Managed Bitcoin Derivatives Program Designed to Generate Volatility Income and Hedge Downside Exposure

April 24, 2026 | businesswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

LITS, NAKA, DFDV, and HSDT Company Descriptions

DeFi Development NASDAQ:DFDV

$5.25 -0.12 (-2.23%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$5.41 +0.16 (+3.03%)

As of 10/2/2026 07:58 PM Eastern

We are a B2B fintech marketplace connecting commercial property borrowers and lenders with a human touch. We seek to revolutionize the commercial real estate lending market by making it hyper-efficient, transparent, and accessible to all rather than the few. Through our online platform, we provide technology that connects commercial mortgage borrowers looking for capital to refinance, build, or purchase commercial property, including, but not limited to, apartment buildings, to commercial property lenders. Borrowers include, but are not limited to, owners, operators, and developers of commercial real estate including multifamily properties and most recently, a growing segment of small business owners, which we believe represents a significant growth opportunity. Lenders include small banks, credit unions, REITs, Fannie Mae® and Freddie Mac® multifamily lenders, FHA® multifamily lenders, debt funds, CMBS lenders, SBA lenders, and more. We have developed a flexible, two-sided, B2B marketplace that connects commercial borrowers and lenders, with a human touch. Commercial property owners, operators, and developers can quickly create an account on our platform, set up their own profile, and submit and manage loan requests on their dashboard in a digital experience. Our algorithms automatically match borrowers to their best loan options or to our internal capital markets advisors that guide the borrower throughout the process and connect them with a potentially suitable loan product and lender. Originators that work at commercial mortgage lenders can access their accounts on our platform to view, sort, and communicate with their matched borrowers in real-time, tracking their loan progress through our portal. Capital markets advisors that work internally have their own interface that gives them access to targeted loan opportunities empowering them to better assist borrowers in managing their choices, leading to the best possible outcomes for both lenders and borrowers while building trust, all of which is intended to enhance our brand. We believe that as we scale, we can use the same technology to provide similar services across the commercial property and small business value chain. Our mission is to remove frictions from traditional commercial property financing, making it easier and more cost-effective for all parties in the transaction. We intend to disintermediate commercial real estate financing, flattening the playing field for commercial property owners and developers, and lenders of all sizes, democratizing an otherwise fractured and elitist market. We were originally formed as Janover Ventures LLC, a Florida limited liability company, on November 28, 2018, and converted to Janover Inc., a Delaware corporation, on March 9, 2021. We are headquartered at 6401 Congress Avenue, Suite 250, Boca Raton, Florida.

Solana NASDAQ:HSDT

$2.63 +0.01 (+0.38%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$2.60 -0.03 (-1.10%)

As of 10/2/2026 07:59 PM Eastern

Helius Medical Technologies, Inc., a neurotechnology company, focuses on developing, licensing, and acquiring non-implantable technologies for the treatment of symptoms caused by neurological disease or trauma. The company's product is Portable Neuromodulation Stimulator, a non-surgical medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury, as well as to be used in conjunction with supervised therapeutic exercise. The company was incorporated in 2014 and is headquartered in Newtown, Pennsylvania.

Lite Strategy NASDAQ:LITS

$1.38 +0.01 (+0.36%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$1.36 -0.02 (-1.16%)

As of 10/2/2026 07:54 PM Eastern

MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase III clinical trial for the treatment of patients with relapsed/refractory follicular lymphoma, as well as in Phase Ib multi-arm trial to treat B-cell malignancies; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase Ib clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex that is in Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer; and Pracinostat, an oral available histone deacetylase inhibitor, which is in Phase II clinical trial to treat patients with myelodysplastic syndrome. MEI Pharma, Inc. has a license, development, and commercialization agreement with Kyowa Kirin Company; a clinical collaboration with BeiGene, Ltd.; a license, development, manufacturing, and commercialization agreement with Helsinn Healthcare SA; and a license agreement with Presage Biosciences, Inc. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California.

KindlyMD NASDAQ:NAKA

$9.66 +0.55 (+6.04%)

As of 10/2/2026 04:00 PM Eastern

Kindly MD, Inc. (“KindlyMD” or “Kindly”) is a Utah company formed in 2019. KindlyMD is a healthcare data company, focused on holistic pain management and reducing the impact of the opioid epidemic. KindlyMD offers direct health care to patients integrating prescription medicine and behavioral health services to reduce opioid use in the chronic pain patient population. Kindly believes these methods will help prevent and reduce addiction and dependency on opiates. Our specialty outpatient clinical services are offered on a fee-for-service basis. The Company offers evaluation and management, including, but not limited to chronic pain, functional medicine, cognitive behavioral therapy, trauma and addiction therapy, recovery support services, overdose education efforts, peer support, limited urgent care, preventative medicine, medically managed weight loss, and hormone therapy. Through its focus on an embedded model of prescriber and therapist teams, KindlyMD develops patient-specific care programs with a specific mission to reduce opioid use in the patient population while successfully treating patients with effective and evidence-based non-opioid alternatives in close conjunction with behavioral therapy. Beyond its treatment of patients, KindlyMD collects data focused on why and how patients turn to alternative treatments to reduce prescription medication use and addiction. The Company captures all relevant datapoints to assist and appropriately treat each individual patient. This also results in valuable data for the Company and the Company’s investors. We strive to become a source for evidence-based guidelines, data, treatment models, and education in the fight against the opioid crisis in America. Business Revenue Streams We currently earn revenue through (i) patient care services related to medical evaluation and treatment and (ii) product retail sales. Our forecasted plan is to operate across various revenue streams: (i) medical evaluation and treatment visits reimbursed by Medicare, Medicaid, and commercial insurance payers as well as self-pay services, (ii) data collection and research, (iii) education partnerships, (iv) service affiliate agreements, and (v) retail sales. Our principal executive offices are located at 5097 S 900 E, Suite 100 Salt Lake City, UT.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest LITS, NAKA, DFDV, and HSDT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest LITS, NAKA, DFDV, and HSDT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

LITS, NAKA, DFDV, and HSDT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

LITS, NAKA, DFDV, and HSDT Company Descriptions

DeFi Development NASDAQ:DFDV

Solana NASDAQ:HSDT

Lite Strategy NASDAQ:LITS

KindlyMD NASDAQ:NAKA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest LITS, NAKA, DFDV, and HSDT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest LITS, NAKA, DFDV, and HSDT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

LITS, NAKA, DFDV, and HSDT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

LITS, NAKA, DFDV, and HSDT Company Descriptions

DeFi Development NASDAQ:DFDV

Solana NASDAQ:HSDT

Lite Strategy NASDAQ:LITS

KindlyMD NASDAQ:NAKA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools